NCT02006537View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 27, 2014

Study Completion Date

May 27, 2014

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK2256294

GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY